NLX-204

NLX-204 is a drug that as of 2026^[update] is being evaluated to treat depression. It is a selective biased agonist of the serotonin 5-HT1A receptor, distinguished by its preference for activating ERK1/ERK2 phosphorylation pathways.^[1][2]

Other namesNLX204

Drug classSerotonin 5-HT_1A receptor biased agonist

CAS Number

• 2170405-10-2

PubChem CID

• 132256735

Quick facts Clinical data, Other names ...

NLX-204

Clinical data
Other names	NLX204
Drug class	Serotonin 5-HT1A receptor biased agonist
Identifiers
IUPAC name (3-Chloro-4-fluorophenyl)-[4-fluoro-4-[(2-pyridin-2-yloxyethylamino)methyl]piperidin-1-yl]methanone
CAS Number	2170405-10-2
PubChem CID	132256735
ChemSpider	88296509
ChEMBL	ChEMBL4753328
Chemical and physical data
Formula	C20H22ClF2N3O2
Molar mass	409.86 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCC1(CNCCOC2=CC=CC=N2)F)C(=O)C3=CC(=C(C=C3)F)Cl
InChI InChI=1S/C20H22ClF2N3O2/c21-16-13-15(4-5-17(16)22)19(27)26-10-6-20(23,7-11-26)14-24-9-12-28-18-3-1-2-8-25-18/h1-5,8,13,24H,6-7,9-12,14H2 Key:ZMEGJWWPDKBOER-UHFFFAOYSA-N

Close

This compound has demonstrated potent and rapid-acting antidepressant-like effects in preclinical models, with activity comparable to ketamine in reversing symptoms of depression and treatment-resistant depression in rodents. Recent studies suggest that NLX-204 also offers potential benefits reversing memory deficits and anxiety, positioning it as a candidate for a rapid-acting antidepressant therapy.^[3][4]